1
|
Cherrez-Ojeda I, Bousquet J, Giménez-Arnau A, Godse K, Krasowska D, Bartosińska J, Szczepanik-Kułak P, Wawrzycki B, Kolkhir P, Allenova A, Allenov A, Tkachenko S, Teovska Mitrevska N, Mijakoski D, Stoleski S, Kolacinska-Flont M, Kuprys-Lipinska I, Molinska J, Kasperska-Zając A, Zajac M, Zamlynski M, Mihaltan F, Ulmeanu R, Zalewska-Janowska A, Tomaszewska K, Al-Ahmad M, Al-Nesf MA, Ibrahim T, Aqel S, Pesqué D, Rodríguez-González M, Wakida-Kuzunoki GH, Ramon GD, Ramon GN, Neisinger S, Bonnekoh H, Rukhadze M, Khoshkhui M, Fomina D, Larenas-Linnemann D, Košnik M, Oztas Kara R, Caballero López CG, Liu Q, Ivancevich JC, Ensina LF, Rosario N, Kvedariene V, Ben-Shoshan M, Criado RFJ, Bauer A, Cherrez A, Cherrez S, Chong-Neto H, Rojo-Gutierrez MI, Rudenko M, Larco Sousa JI, Lesiak A, Matos E, Tinoco I, Crespo Shijin C, Hinostroza Logroño R, Sagñay JC, Faytong-Haro M, Robles-Velasco K, Zuberbier T, Maurer M. Usage prevalence of angioedema patient-reported outcome measures: results from the UCARE and ACARE PROMUSE study. J Allergy Clin Immunol Pract 2024:S2213-2198(24)00464-1. [PMID: 38734372 DOI: 10.1016/j.jaip.2024.04.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 04/29/2024] [Accepted: 04/30/2024] [Indexed: 05/13/2024]
Affiliation(s)
- Ivan Cherrez-Ojeda
- Universidad de Especialidades Espíritu Santo, School of Medicine, Samborondón, Ecuador; RespiraLab, Research, Guayaquil, Ecuador.
| | - Jean Bousquet
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Ana Giménez-Arnau
- Dermatology Department, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.
| | - Kiran Godse
- Department of Dermatology, D Y. Patil University School of Medicine, Navi Mumbai, India.
| | - Dorota Krasowska
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Joanna Bartosińska
- Department of Cosmetology and Aestetic Medicine Medical University of Lublin Poland; Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, Poland.
| | - Paulina Szczepanik-Kułak
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Bartłomiej Wawrzycki
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Pavel Kolkhir
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Anastasiia Allenova
- Laboratory of Immune-mediated skin diseases, Institute of Regenerative; Medicine, Biomedical Science & Technology Park, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
| | - Andrey Allenov
- Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation; State Budgetary Healthcare Institution of the City of Moscow "City Polyclinic No. 2 10 of the Department of Health of the City of Moscow", Moscow, Russian Federation; Federal State Budgetary Scientific Institution "N.A. Semashko National Research Institute of Public Health", Moscow, Russian Federation.
| | - Sergey Tkachenko
- Russian Medical Academy of Сontinuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.
| | - Natasa Teovska Mitrevska
- Remedika general hospital dermatology department, Skopje Republic of North Macedonia; International Balkan University (IBU), Skopje Republic of North Macedonia.
| | - Dragan Mijakoski
- Institute of Occupational health of RNM-Skopje, Republic of North Macedonia; Faculty of Medicine, SS Cyril and Methodius, University in Skopje, Skopje Republic of North Macedonia.
| | - Sasho Stoleski
- Institute of Occupational health of RNM-Skopje, Republic of North Macedonia; Faculty of Medicine, SS Cyril and Methodius, University in Skopje, Skopje Republic of North Macedonia.
| | - Marta Kolacinska-Flont
- Department of Internal Medicine, Asthma and Allergy, Barlicki Memorial Hospital, Medical University of Lodz, Poland.
| | - Izabela Kuprys-Lipinska
- Department of Internal Medicine, Asthma and Allergy, Barlicki Memorial Hospital, Medical University of Lodz, Poland.
| | - Joanna Molinska
- Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland.
| | - Alicja Kasperska-Zając
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | - Magdalena Zajac
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | - Mateusz Zamlynski
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | | | | | - Anna Zalewska-Janowska
- Medical University of Lodz, Chair of Clinical Immunology and Rheumatology, Department of Psychodermatology, Lodz, Poland.
| | - Katarzyna Tomaszewska
- Medical University of Lodz, Chair of Clinical Immunology and Rheumatology, Department of Psychodermatology, Lodz, Poland.
| | - Mona Al-Ahmad
- Microbiology Department, College of Medicine, Kuwait University, Kuwait.
| | - Maryam Ali Al-Nesf
- Allergy and Immunology Division, Medicine Department, Hamad Medical Corporation, Doha, Qatar.
| | - Tayseer Ibrahim
- Allergy and Immunology Division, Medicine department, Hamad Medical Corporation, Doha, Qatar.
| | - Sami Aqel
- Allergy and Immunology Division, Medicine department, Hamad Medical Corporation, Doha, Qatar.
| | - David Pesqué
- Department of Dermatology, Hospital del Mar, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB). Barcelona (Spain).
| | | | | | - German D Ramon
- Instituto de Alergia e Inmunologia del Sur, Bahia Blanca, Argentina, GA2LEN Ucare/Adcare/Acare center.
| | - Gonzalo N Ramon
- Instituto de Alergia e Inmunologia del Sur, Bahia Blanca, Argentina, GA2LEN Ucare/Adcare/Acare center.
| | - Sophia Neisinger
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Hanna Bonnekoh
- Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
| | - Maia Rukhadze
- Center Allergy&Immunology, Tbilisi, Georgia / Geomedi Teaching University, Faculty of Medicine, Tbilisi, Georgia.
| | - Maryam Khoshkhui
- Allergy Research Center, Mashhad University of Medical Science(MUMS), Mashhad, Iran.
| | - Daria Fomina
- Moscow Practical and Research Center of Allergy and Immunology, Clinical City Hospital, Moscow, Russian Federation; Moscow Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Astana Medical University, Moscow, Russian Federation.
| | | | - Mitja Košnik
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; Medical Faculty, University of Ljubljana, Slovenia.
| | - Rabia Oztas Kara
- Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
| | | | - Qiang Liu
- 2nd Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
| | | | - Luis Felipe Ensina
- Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo and CPAlpha Clinical Research Center., São Paulo, Brazil.
| | - Nelson Rosario
- Urticaria Center of Reference and Excellence (UCARE), Federal University of Parana, Rua General Carneiro, Curitiba, Brazil.
| | - Violeta Kvedariene
- Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Institute of Clinical Medicine, Clinic of Chest diseases, Immunology and Allergology, Faculty of Medicine, Vilnius, Lithuania.
| | - Moshe Ben-Shoshan
- Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University Health Center, Montreal, QC, Canada.
| | | | - Andrea Bauer
- Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
| | - Annia Cherrez
- Department of Dermatology, Venerology, and Allergology, Charité Universitätsmedizin Berlin.
| | - Sofia Cherrez
- Gemeinschaftspraxis PD Dr. Jung & Kollegen, Krämpferstr. 6, Erfurt.
| | - Herberto Chong-Neto
- Department of Pediatrics, Hospital de Clínicas, Federal University of Paraná (UFPR), Curitiba, Brazil.
| | | | - Michael Rudenko
- London Allergy and Immunology Centre, London United Kingdom.
| | | | - Aleksandra Lesiak
- Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland.
| | - Edgar Matos
- Instituto Nacional de Salud del Nino, Lima, Peru.
| | | | | | | | | | - Marco Faytong-Haro
- Sociology and Demography Department, The Pennsylvania State University, University Park, PA, USA; Ecuadorian Development Research Lab, Daule, Guayas, Ecuador; Universidad Espíritu Santo, Samborondon, Ecuador; Respiralab Research Group, Guayaquil, Ecuador.
| | - Karla Robles-Velasco
- Universidad Espíritu Santo, Samborondon, Ecuador; Respiralab Research Group, Guayaquil, Ecuador.
| | - Torsten Zuberbier
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Marcus Maurer
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| |
Collapse
|
2
|
Cherrez-Ojeda I, Bousquet J, Giménez-Arnau A, Godse K, Krasowska D, Bartosińska J, Szczepanik-Kułak P, Wawrzycki B, Kolkhir P, Allenova A, Allenov A, Tkachenko S, Teovska Mitrevska N, Mijakoski D, Stoleski S, Kolacinska-Flont M, Kuprys-Lipinska I, Molinska J, Kasperska-Zając A, Zajac M, Zamlynski M, Mihaltan F, Ulmeanu R, Zalewska-Janowska A, Tomaszewska K, Al-Ahmad M, Al-Nesf MA, Ibrahim T, Aqel S, Pesqué D, Rodríguez-González M, Wakida-Kuzunoki GH, Ramon GD, Ramon GN, Neisinger S, Bonnekoh H, Rukhadze M, Khoshkhui M, Fomina D, Larenas-Linnemann D, Košnik M, Oztas Kara R, Caballero López CG, Liu Q, Ivancevich Juan C, Ensina LF, Rosario N, Kvedariene V, Ben-Shoshan M, Criado RFJ, Bauer A, Cherrez A, Chong-Neto H, Rojo-Gutierrez MI, Rudenko M, Larco Sousa JI, Lesiak A, Matos E, Muñoz N, Tinoco I, Moreno J, Crespo Shijin C, Hinostroza Logroño R, Sagñay JC, Faytong-Haro M, Robles-Velasco K, Zuberbier T, Maurer M. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria are Underused in Clinical Practice. J Allergy Clin Immunol Pract 2024:S2213-2198(24)00349-0. [PMID: 38604531 DOI: 10.1016/j.jaip.2024.03.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 03/25/2024] [Accepted: 03/26/2024] [Indexed: 04/13/2024]
Abstract
BACKGROUND Patient-reported outcome measures (PROMs) are validated and standardized tools that complement physician evaluations and guide treatment decisions. PROMs are crucial for monitoring atopic dermatitis (AD) and chronic urticaria (CU) in clinical practice, but there are unmet needs and knowledge gaps regarding their use in clinical practice. OBJECTIVE We investigated the global real-world use of AD and CU PROMs in allergology and dermatology clinics as well as their associated local and regional networks. METHODS Across 72 specialized allergy and dermatology centers and their local and regional networks, 2,534 physicians in 73 countries completed a 53-item questionnaire on the use of PROMs for AD and CU. RESULTS Of 2,534 physicians, 1,308 were aware of PROMs. Of these, 14% and 15% used PROMs for AD and CU, respectively. Half of physicians who use PROMs do so only "rarely" or "sometimes". AD and CU PROM usage is associated with being female, younger, and a dermatologist. POSCORAD and UAS were the most utilized PROMs for AD and CU, respectively. Monitoring disease control and activity are the main drivers of the use of PROMs. Time constraints were the primary obstacle to using PROMs, followed by the impression that patients dislike PROMs. AD and CU PROM users would like training in selecting the proper PROM. CONCLUSION Even though PROMs offer several benefits, their use in routine practice is suboptimal, and physicians perceive barriers to their use. It is essential to attain higher levels of PROM implementation in accordance with national and international standards.
Collapse
Affiliation(s)
- Ivan Cherrez-Ojeda
- Universidad de Especialidades Espíritu Santo, School of Medicine, Samborondón, Ecuador; RespiraLab, Research, Guayaquil, Ecuador.
| | - Jean Bousquet
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Ana Giménez-Arnau
- Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.
| | - Kiran Godse
- Department of Dermatology, D Y. Patil University School of Medicine, Mumbai, India.
| | - Dorota Krasowska
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Joanna Bartosińska
- Department of Cosmetology and Aestetic Medicine Medical University of Lublin Poland; Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, Poland.
| | - Paulina Szczepanik-Kułak
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Bartłomiej Wawrzycki
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Pavel Kolkhir
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Anastasiia Allenova
- Laboratory of Immune-mediated skin diseases, Institute of Regenerative Medicine, Biomedical Science & Technology Park, I.M. Sechenov First Moscow State Medical University (SechenovUniversity), Moscow, Russian Federation; Medical Research and Education Center, M.V. Lomonosov Moscow State University, Moscow, Russian Federation.
| | - Andrey Allenov
- Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation; State Budgetary Healthcare Institution of the City of Moscow "City Polyclinic No. 2 10 of the Department of Health of the City of Moscow", Moscow, Russian Federation; Federal State Budgetary Scientific Institution "N.A. Semashko National Research Institute of Public Health", Moscow, Russian Federation.
| | - Sergey Tkachenko
- Russian Medical Academy of Сontinuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.
| | - Natasa Teovska Mitrevska
- Remedika general hospital dermatology department, Skopje Republic of North Macedonia; International Balkan University (IBU), Skopje Republic of North Macedonia.
| | - Dragan Mijakoski
- Institute of Occupational health of RNM-Skopje, Republic of North Macedonia; Faculty of Medicine, SS Cyril and Methodius, University in Skopje, Skopje Republic of North Macedonia.
| | - Sasho Stoleski
- Institute of Occupational health of RNM-Skopje, Republic of North Macedonia; Faculty of Medicine, SS Cyril and Methodius, University in Skopje, Skopje Republic of North Macedonia.
| | - Marta Kolacinska-Flont
- Department of Internal Medicine, Asthma and Allergy, Barlicki Memorial Hospital, Medical University of Lodz, Poland.
| | - Izabela Kuprys-Lipinska
- Department of Internal Medicine, Asthma and Allergy, Barlicki Memorial Hospital, Medical University of Lodz, Poland.
| | - Joanna Molinska
- Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland.
| | - Alicja Kasperska-Zając
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | - Magdalena Zajac
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | - Mateusz Zamlynski
- European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) & Department of Clinical Allergology and Urticaria of Medical University of Silesia, Poland.
| | | | | | - Anna Zalewska-Janowska
- Medical University of Lodz, Chair of Clinical Immunology and Rheumatology, Department of Psychodermatology, Lodz, Poland.
| | - Katarzyna Tomaszewska
- Medical University of Lodz, Chair of Clinical Immunology and Rheumatology, Department of Psychodermatology, Lodz, Poland.
| | - Mona Al-Ahmad
- Microbiology Department, Faculty of Medicine, Kuwait University, Safat, Kuwait.
| | - Maryam Ali Al-Nesf
- Allergy and Immunology Division, Medicine Department, Hamad Medical Corporation, Doha, Qatar.
| | - Tayseer Ibrahim
- Allergy and Immunology Division, Medicine department, Hamad Medical Corporation, Doha, Qatar.
| | - Sami Aqel
- Allergy and Immunology Division, Medicine department, Hamad Medical Corporation, Doha, Qatar.
| | - David Pesqué
- Department of Dermatology, Hospital del Mar, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB). Barcelona (Spain).
| | | | | | - German D Ramon
- Instituto de Alergia e Inmunologia del Sur, Bahia Blanca, Argentina, GA2LEN Ucare/Adcare/Acare center.
| | - Gonzalo N Ramon
- Instituto de Alergia e Inmunologia del Sur, Bahia Blanca, Argentina, GA2LEN Ucare/Adcare/Acare center.
| | - Sophia Neisinger
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Hanna Bonnekoh
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Maia Rukhadze
- Center Allergy&Immunology, Tbilisi, Georgia / Geomedi Teaching University, Faculty of Medicine, Tbilisi, Georgia.
| | - Maryam Khoshkhui
- Allergy Research Center, Mashhad University of Medical Science(MUMS), Mashhad, Iran.
| | - Daria Fomina
- Moscow Practical and Research Center of Allergy and Immunology, Clinical City Hospital, Moscow, Russian Federation; Moscow Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Astana Medical University, Moscow, Russian Federation.
| | | | - Mitja Košnik
- Allergy University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia Medical Faculty, University of Ljubljana, Slovenia.
| | - Rabia Oztas Kara
- Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
| | | | - Qiang Liu
- 2nd Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
| | | | - Luis Felipe Ensina
- Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo and CPAlpha Clinical Research Center., São Paulo, Brazil.
| | - Nelson Rosario
- Urticaria Center of Reference and Excellence (UCARE), Federal University of Parana, Rua General Carneiro, Curitiba, Brazil.
| | - Violeta Kvedariene
- Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Institute of Clinical Medicine, Clinic of Chest diseases, Immunology and Allergology, Faculty of Medicine, Vilnius, Lithuania.
| | - Moshe Ben-Shoshan
- Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University Health Center, Montreal, QC, Canada.
| | | | - Andrea Bauer
- Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
| | - Annia Cherrez
- Department of Dermatology and Allergy, Charité- Universitätsmedizin Berlin, Berlin, Germany.
| | - Herberto Chong-Neto
- Department of Pediatrics, Hospital de Clínicas, Federal University of Paraná (UFPR), Curitiba, Brazil.
| | | | - Michael Rudenko
- London Allergy and Immunology Centre, London United Kingdom.
| | | | - Aleksandra Lesiak
- Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland.
| | - Edgar Matos
- Instituto Nacional de Salud del Nino, Lima, Peru.
| | - Nelson Muñoz
- Specialist Centre: Muñoz Alergias y Pediatría, Riobamba - Ecuador.
| | | | | | | | | | | | - Marco Faytong-Haro
- Sociology and Demography Department, The Pennsylvania State University, University Park, PA, USA; Ecuadorian Development Research Lab, Daule, Guayas, Ecuador; Universidad Espíritu Santo, Samborondon, Ecuador; Respiralab Research Group, Guayaquil, Ecuador.
| | - Karla Robles-Velasco
- Universidad Espíritu Santo, Samborondon, Ecuador; Respiralab Research Group, Guayaquil, Ecuador.
| | - Torsten Zuberbier
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| | - Marcus Maurer
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
| |
Collapse
|
3
|
Szczepanik-Kułak P, Bartosińska J, Kowalczuk D, Gerkowicz A, Bojar I, Kwaśny M, Krasowska D. Efficacy of photodynamic therapy using ALAHCl in gel with a lipid nanoemulsion and MALHCl in cream in superficial basal cell carcinoma. Ann Agric Environ Med 2024; 31:94-99. [PMID: 38549482 DOI: 10.26444/aaem/183059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/02/2024]
Abstract
INTRODUCTION AND OBJECTIVE Photodynamic therapy (PDT) is a therapeutic option for low-risk basal cell carcinoma (BCC). The aim of the study was to assess the efficacy of topical PDT in the treatment of superficial BCC (sBCC) using two different photosensitizers: aminolevulinic acid hydrochloride (ALA-HCl) in a gel formulation with a lipid nanoemulsion (ALA-HCl in gel) and ALA methyl ester hydrochloride (MAL-HCl) in a cream formulation (MAL-HCl in cream). MATERIAL AND METHODS 21 patients were treated twice with a one week interval between treatments. The formulations were applied onto lesions: 10 patients were treated with MAL-HCl in cream, and 11 with ALA-HCl in gel. After three hours of incubation and removing the preparations, fluorescence was assessed. The skin areas were then irradiated with red light 630 ± 5 nm. RESULTS At the follow-up visit 12 weeks after the second treatment, complete clinical remission was found in 82% after ALA-HCl in gel and in 80% after MAL-HCl in cream. An excellent cosmetic result was found in 96% of patients after MALHCl in cream and in 100% after ALA-HCl in gel. Faster skin healing and less post-inflammatory hyperpigmentation during follow-up visits was observed after treatment with ALA-HCl in gel. CONCLUSIONS Both formulations - ALA-HCl in gel and MAL-HCl in cream - were highly effective photosensitisers for PDT. The advantage of ALA-HCl in a gel formulation with a lipid nanoemulsion was faster skin healing, resulting in better cosmetic results.
Collapse
Affiliation(s)
- Paulina Szczepanik-Kułak
- Department of Dermatology, Venereology and Paediatric Dermatology, Medical University, Lublin, Poland
| | - Joanna Bartosińska
- Department of Dermatology, Venereology and Paediatric Dermatology, Medical University, Lublin, Poland
- Department of Cosmetology and Aesthetic Medicine, Medical University, Lublin, Poland
| | - Dorota Kowalczuk
- Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University, Lublin, Poland
| | - Agnieszka Gerkowicz
- Department of Dermatology, Venereology and Paediatric Dermatology, Medical University, Lublin, Poland
| | - Iwona Bojar
- Department of Women's Health, Institute of Rural Health, Lublin, Poland
| | - Mirosław Kwaśny
- Institute of Optoelectronics, Military University of Technology, Warsaw, Poland
| | - Dorota Krasowska
- Department of Dermatology, Venereology and Paediatric Dermatology, Medical University, Lublin, Poland
| |
Collapse
|
4
|
Szczepanik-Kułak P, Michalska-Jakubus M, Kowal M, Krasowska D. Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea. J Clin Med 2022; 11:6375. [PMID: 36362603 PMCID: PMC9655385 DOI: 10.3390/jcm11216375] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 09/22/2022] [Accepted: 10/27/2022] [Indexed: 07/27/2023] Open
Abstract
Morphea/localized scleroderma (LoS) represents an inflammatory-sclerotic skin disease, the pathogenesis of which is not fully understood. Given the important role of IL-1 family cytokines in the development and therapy of inflammatory diseases, including systemic sclerosis, we analyzed the clinical significance of serum levels of selected IL-1 family cytokines (IL-1α, IL-1β, IL-18, IL-33, IL-37 and IL-38) in LoS patients (n = 30) using the standardized disease assessment tools and comparison to healthy controls (n = 28). We also compared the pre- and post-treatment concentrations, i.e., before and after systemic (glucocorticosteroids and/or methotrexate) and/or topical (topical glucocorticosteroids and/or calcineurin inhibitors). Our findings did not reveal significant differences in baseline IL-1α, IL-1β, IL-18, IL-33, IL-37 and IL-38 levels between LoS group and HCs; however, after treatment, there were marked changes in concentrations of IL-1α and IL-33 within LoS group as well as in comparison to HCs. We also found significant negative correlations between PGA-A and IL-1α concentration as well as between mLoSSI and IL-1α after treatment. Furthermore, we showed an inverse correlation of baseline IL-1β levels with mLoSSI scores of borderline significance. We believe that IL-1α and IL-33, as well as Il-1β, may be potential mediators and targets of interest in LoS.
Collapse
|
5
|
Szczepanik-Kułak P, Michalak-Stoma A, Krasowska D. Usefulness of Dermoscopy in Localized Scleroderma (LoS, Morphea) Diagnosis and Assessment-Monocentric Cross-Sectional Study. J Clin Med 2022; 11:jcm11030764. [PMID: 35160216 PMCID: PMC8836985 DOI: 10.3390/jcm11030764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Revised: 01/28/2022] [Accepted: 01/29/2022] [Indexed: 11/16/2022] Open
Abstract
Morphea, also known as localized scleroderma (LoS), is a chronic autoimmune disease of the connective tissue. The clinical picture of LoS distinguishes between active and inactive lesions. Sometimes the clinical findings are challenging to identify, and therefore, the need for additional methods is emphasized. Our study aimed to demonstrate the characteristic dermoscopic features in morphea skin lesions, focusing on demonstrating features in active and inactive lesions. In our patients (n = 31) with histopathologically proven LoS, we performed clinical evaluation of lesions (n = 162): active/inactive and according to both disease activity (modified localized scleroderma severity index, mLoSSI) and damage (localized scleroderma skin damage index, LoSDI) parameters. In addition, we took into account compression locations to determine whether skin trauma, a known etiopathogenetic factor in LoS, affects the dermoscopic pattern of the lesions. We performed a dermoscopy of the lesions, categorizing the images according to the severity within the observed field. We showed that within the active lesions (clinically and with high mLoSSI), white clouds and linear branching vessels had the highest severity. These features decreased within the observed field in inactive lesions and with high LoSDI. Brownish structureless areas were most intense in inactive lesions with high LoSDI. Erythematous areas, linear branching vessels, dotted vessels, and crystalline structures were statistically significant for pressure locations. We have shown dermoscopy is a valuable tool to assess the activity or inactivity of lesions, which translates into appropriate therapeutic decisions and the possibility of monitoring the patient during and after therapy for possible relapse.
Collapse
|
6
|
Gerkowicz A, Szczepanik-Kułak P, Krasowska D. Photodynamic Therapy in the Treatment of Vulvar Lichen Sclerosus: A Systematic Review of the Literature. J Clin Med 2021; 10:5491. [PMID: 34884193 PMCID: PMC8658411 DOI: 10.3390/jcm10235491] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 11/14/2021] [Accepted: 11/17/2021] [Indexed: 11/16/2022] Open
Abstract
Vulvar lichen sclerosus (VLS) is a chronic inflammatory disease involving the genital skin and mucous membrane. Patients exhibit focal atrophy and destructive scarring, with an increased risk of malignant transformation. Due to objective symptoms as well as subjective complaints, patients with VLS experience emotional distress, lowered mood, and sexual dysfunction, which is reflected in impaired health-related quality of life. Thus, the necessity of implementing appropriate therapy at the earliest possible stage of the disease in order to avoid serious complications is highlighted. We presented the systematic review of available literature, performed with MEDLINE, Cinahl, Central, Scopus, and Web of Science databases. We identified a total of twenty relevant studies which indicate that photodynamic therapy (PDT) is a valuable therapeutic modality in the treatment of VLS.
Collapse
Affiliation(s)
| | - Paulina Szczepanik-Kułak
- Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland; (A.G.); (D.K.)
| | | |
Collapse
|
7
|
Polkowska-Pruszyńska B, Gerkowicz A, Szczepanik-Kułak P, Krasowska D. Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature. Arch Dermatol Res 2018; 311:1-8. [PMID: 30382339 PMCID: PMC6326989 DOI: 10.1007/s00403-018-1874-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 09/27/2018] [Accepted: 10/26/2018] [Indexed: 02/08/2023]
Abstract
Systemic sclerosis (SSc) is a chronic, connective tissue disease with an autoimmune pattern characterized by inflammation, fibrosis and microcirculation changes leading to internal organs malfunctions. Recently, the presence of uncharacteristic gastrointestinal symptoms in the course of SSc has been underlined. The possible cause of such clinical presentation is the small intestinal bacterial overgrowth (SIBO). Nevertheless, these manifestations resulting from gastrointestinal tract hypomotility may occur in numerous disease entities. The systematic review of the literature was performed on MEDLINE database using the relevant MeSH terms including all sub-headings. After further investigation, the initial number of 56 records was limited to 7 results. The study analysis showed an increased presence of SIBO in 39% of patients suffering from SSc. The average SSc duration was longer in SSc patients with coexisting SIBO. SIBO remains a diagnostic and therapeutic challenge and therefore is a significant clinical problem among patients suffering from SSc.
Collapse
Affiliation(s)
- Beata Polkowska-Pruszyńska
- Chair and Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
| | - Agnieszka Gerkowicz
- Chair and Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland
| | - Paulina Szczepanik-Kułak
- Chair and Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland
| | - Dorota Krasowska
- Chair and Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland
| |
Collapse
|